Form 6-K/A Biodexa Pharmaceuticals For: Jun 30

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 6-K/A

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934

 

For the month of June 2026
Commission File Number 001-37652

 

Biodexa Pharmaceuticals PLC

(Translation of registrant’s name into English)
1 Caspian Point,
Caspian Way,
Cardiff, CF10 4DQ, United Kingdom
(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F x Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

 

EXPLANATORY NOTE 

 

 

This Amendment No. 1 on Form 6-K/A (“Amendment No.1”) amends the Current Report on Form 6-K of Biodexa Pharmaceuticals PLC (the “Company”) filed with the Securities and Exchange Commission (the “SEC”) on June 30, 2026. This Amendment No. 1 is being filed solely for the purpose of filing Exhibit 5.1.

 

Other than as expressly set forth above, this Form 6-K/A does not, and does not purport to, amend, update or restate the information in any other item of the Form 6-K, or reflect any events that have occurred after the Form 6-K was originally filed. 

 

The information included in this report on Form 6-K, shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File No. 333-209365) and Form F-3 (File No. 333-290554) of the Company (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

 

 

SUBMITTED HEREWITH

 

Attached to the Registrant’s Form 6-K filing for the month of June 2026 is:

 

Exhibit No.		Description
5.1		Opinion of Stephenson Harwood LLP

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

	Biodexa Pharmaceuticals PLC
Date: June 30, 2026	By:	/s/ Stephen Stamp
		Stephen Stamp
		Chief Executive Officer

 

 

 

 

 

ATTACHMENTS / EXHIBITS

EXHIBIT 5.1

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• IMAX and CGV Continue Partnership With Three IMAX With Laser Locations In Vietnam
• /C O R R E C T I O N -- 10,000 Degrees/
• Back to School, Back to Being Kids: Arshiner’s New Campus Collection Brings Comfort and Energy to the Classroom